R-3 10MG

Retatrutide (often called “reta”) is an experimental triple-hormone receptor agonist injection that targets GLP-1, GIP, and glucagon receptors. It is currently in Phase 3 clinical trials for weight loss and obesity, showing average weight reductions of up to 28% to 30% in studies